# Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer

Source: https://onco.cc/trials/nct03315754/  
OnCo record `nct03315754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.

## Summary

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer is a phase 2 interventional study registered as NCT03315754 by Steba Biotech S.A., with 50 participants recorded, started 2017-10-02 and reaching its primary completion in 2020-11-02. Interventions recorded: TOOKAD Soluble 4 mg/kg. Conditions recorded: Localized Prostate Cancer.

Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03315754
- Phase: 2
- Setting: Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.
- Sponsor: Steba Biotech S.A.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT03315754: https://clinicaltrials.gov/study/NCT03315754

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Padeliporfin](https://onco.cc/drugs/padeliporfin/)
- companies: [Steba Biotech](https://onco.cc/companies/steba-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct03315754.json